Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Recro Pharma Inc.

    NASDAQ: REPH · Real-Time Price · USD
    2.09
    -0.01 (-0.48%)
    At close: Mar 22, 2022, 5:00 AM

    Recro Pharma Statistics

    Share Statistics

    Recro Pharma has 84.89M shares outstanding. The number of shares has increased by 0% in one year.

    Shares Outstanding

    n/a
    		 84.89M

    Shares Change (YoY)

    n/a
    		 0%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 69.97M

    Failed to Deliver (FTD) Shares

    n/a
    		 n/a

    FTD / Avg. Volume

    n/a
    		 n/a

    Short Selling Information

    The latest short interest is 629.29K, so 0% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 629.29K

    Short % of Shares Out

    n/a
    		 n/a

    Short % of Float

    n/a
    		 n/a

    Short Ratio (days to cover)

    n/a
    		 4.05

    Valuation Ratios

    The PE ratio is -14993.9 and the forward PE ratio is null. Recro Pharma's PEG ratio is 149.98.

    PE Ratio

    n/a
    		 -14993.9

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 2103.12

    Forward PS

    n/a
    		 n/a

    PB Ratio

    n/a
    		 3392.75

    P/FCF Ratio

    n/a
    		 -21535.27

    PEG Ratio

    n/a
    		 149.98
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Recro Pharma.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.07, with a Debt / Equity ratio of 0.72.

    Current Ratio

    n/a
    		 1.07

    Quick Ratio

    n/a
    		 0.86

    Debt / Equity

    n/a
    		 0.72

    Debt / EBITDA

    n/a
    		 -11.76

    Debt / FCF

    n/a
    		 -4.55

    Interest Coverage

    n/a
    		 0.36

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $511,540.54

    Profits Per Employee

    n/a
    		 $-71,751.35

    Employee Count

    n/a
    		 185

    Asset Turnover

    n/a
    		 0.62

    Inventory Turnover

    n/a
    		 7.45

    Taxes

    Income Tax

    n/a
    		 132K

    Effective Tax Rate

    n/a
    		 -1%

    Stock Price Statistics

    The stock price has increased by 0% in the last 52 weeks. The beta is 1.12, so Recro Pharma's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.12

    52-Week Price Change

    n/a
    		 n/a

    50-Day Moving Average

    n/a
    		 1.71

    200-Day Moving Average

    n/a
    		 n/a

    Relative Strength Index (RSI)

    n/a
    		 67.93

    Average Volume (20 Days)

    n/a
    		 128,488

    Income Statement

    In the last 12 months, Recro Pharma had revenue of 94.64M and earned -13.27M in profits. Earnings per share was 0.

    Revenue

    n/a
    		 94.64M

    Gross Profit

    n/a
    		 18.14M

    Operating Income

    n/a
    		 -3.57M

    Net Income

    n/a
    		 -13.27M

    EBITDA

    n/a
    		 -3.57M

    EBIT

    n/a
    		 -23.11M

    Earnings Per Share (EPS)

    n/a
    		 0
    Full Income Statement

    Balance Sheet

    The company has 8.1M in cash and 42.01M in debt, giving a net cash position of -33.92M.

    Cash & Cash Equivalents

    n/a
    		 8.1M

    Total Debt

    n/a
    		 42.01M

    Net Cash

    n/a
    		 -33.92M

    Retained Earnings

    n/a
    		 -278.91M

    Total Assets

    n/a
    		 153.47M

    Working Capital

    n/a
    		 3.47M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -1M and capital expenditures -8.24M, giving a free cash flow of -9.24M.

    Operating Cash Flow

    n/a
    		 -1M

    Capital Expenditures

    n/a
    		 -8.24M

    Free Cash Flow

    n/a
    		 -9.24M

    FCF Per Share

    n/a
    		 0
    Full Cash Flow Statement

    Margins

    Gross margin is 19.17%, with operating and profit margins of -3.78% and -14.03%.

    Gross Margin

    n/a
    		 19.17%

    Operating Margin

    n/a
    		 -3.78%

    Pretax Margin

    n/a
    		 -13.89%

    Profit Margin

    n/a
    		 -14.03%

    EBITDA Margin

    n/a
    		 -3.78%

    EBIT Margin

    n/a
    		 -3.78%

    FCF Margin

    n/a
    		 -9.77%

    Dividends & Yields

    REPH does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for REPH.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Nov 22, 2019. It was a forward split with a ratio of 223:200.

    Last Split Date

    n/a
    		 Nov 22, 2019

    Split Type

    n/a
    		 forward

    Split Ratio

    n/a
    		 223:200

    Scores

    Altman Z-Score

    n/a
    		 -1.25

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist